Thryv Therapeutics announces $30 million financing to launch ASPIRE-HF study
The company secured $30 million Series B financing led by InClin, Inc. to fund the Phase 2a ASPIRE-HF study in heart failure with reduced ejection fraction and QTc prolongation, which opens for enrollment in early 2027. Wave II, a Phase 2/3 study of THRV-1268 in Long QT Syndrome, has completed enrollment of its first efficacy cohort, with data expected in early 2027.
Primary source
Company press release (PR Newswire), November 3, 2026
Thryv Therapeutics Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Efficacy Cohort Fully Enrolled in Long QT Syndrome
Machine-summarized from the source above; not independently reported. How we use automation